Table 1.
Major COVID-19 vaccines approved by at least one country, and paediatric age indications*
| Vaccine type | Vaccine name | Manufacturer and country | Initial age indications (years) | Paediatric age indication (years) | Earliest approval date for children (country) | |
| 1 | messenger RNA (mRNA) | BNT162b2 | Pfizer-BioNTech (USA/Germany) | ≥16 | 12–15 5–11 |
10 May 2021 (USA)12 29 October 2021 (USA)13 |
| 2 | mRNA-1273 | Moderna (USA) | ≥18 | 12–17 | 23 July 2021 (European Union)19 | |
| 3 | Viral vector | Ad26.COV2.S | Johnson & Johnson/Janssen (USA/Belgium) | ≥18 | – | – |
| 4 | AZD1222 | Oxford-AstraZeneca (UK) | ≥18 | – | – | |
| 5 | Covishield | Serum Institute of India (India) | ≥18 | – | – | |
| 6 | Sputnik Light | Gamaleya (Russia) | ≥18 | – | – | |
| 7 | Sputnik V | Gamaleya (Russia) | ≥18 | – | – | |
| 8 | Inactivated virus | BBIBP-CorV | Sinopharm (China) | ≥18 | 3–17 | 18 August 2021 (China)17 |
| 9 | CoronaVac | Sinovac (China) | ≥18 | 3–17 | 6 June 2021 (China)18 | |
| 10 | Covaxin | Bharat Biotech (India) | ≥18 | 2–17 | 12 October 2021 (India)15 | |
| 11 | Protein based | Corbevax | Biological-E (India) | ≥18 | – | – |
| 12 | Covovax | Serum Institute of India (India) | ≥18 | – | – | |
| 13 | NVX-CoV2373 | Novavax (USA) | ≥18 | – | – | |
| 14 | DNA | ZyCoV-D | Zydus Cadila (India) | ≥12 | 12–17 | 20 August 2021 (India)35 |
*As of 14 January 2022.